Search clinical trials for: pediatric leukemia myelodysplastic syndrome azacitidine

Total 56376 results

Millennium Pharmaceuticals, Inc.

Completed

A Study of Pevonedistat in Adult East Asian Participants

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Japan, Taiwan, Korea, Republic of
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Acute Myeloid Leukemia | Down Syndrome | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myeloid Leukemia Associated With Down Syndrome

United States, Canada, Saudi Arabia, Puerto Rico, Australia, New Zealand
Universitätsklinikum Hamburg-Eppendorf

Completed

5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Germany
Nanexa AB
Uppsala University

Completed

Pharmacokinetics, Tolerability and Safety of NEX-18a

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Sweden
Novartis Pharmaceuticals

Completed

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Myelodysplastic Syndromes | Bone Marrow Diseases | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Preleukemia | Chronic Myelomonocytic Leukemia

United States, France, Australia, Netherlands, Spain, Germany, United Kingdom, Finland
Bellicum Pharmaceuticals

Terminated

Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Myelodysplastic Syndrome | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child

United Kingdom, Italy
Federal Research Institute of Pediatric Hematology...

Active, not recruiting

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Myelodysplastic Syndromes | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Myeloblastic Leukemia | Malignant Lymphoma | Biphenotypic Acute Leukemia

Russian Federation
Bellicum Pharmaceuticals

Terminated

Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Primary Immunodeficiency | Anemia, Sickle Cell | Hemoglobinopathies | Fanconi Anemia | Anemia, Aplastic | Thalassemia | Cytopenia | Diamond Blackfan Anemia | Leukemia, Acute Myeloid (AML), Child

Italy
University of Leipzig
Millennium Pharmaceuticals, Inc.

Completed

Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Myelodysplastic Syndromes | Minimal Residual Disease | Acute Myeloid Leukemia in Remission

Germany
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
Gamida Cell ltd

Active, not recruiting

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Lymphoma | Acute Leukemia | Hematological Malignancies | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

Spain, United States, United Kingdom, Israel, Singapore, Brazil, Italy, France, Netherlands, Portugal
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic... and other conditions

United States, Israel, India
Incyte Corporation

Terminated

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Solid Tumors and Hematologic Malignancy

United States, Netherlands, Belgium
Bristol-Myers Squibb

Completed

A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) (DIM Vidaza)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

China
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
AbbVie
Celgene; Genentech, Inc.

Completed

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Germany
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | AML | Myelodysplastic Syndrome | MDS | Non-Hodgkins Lymphoma | NHL

United States, Australia, Italy, France, Greece, Japan
Federal Research Institute of Pediatric Hematology...

Completed

CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT

Lymphoma | Myelodysplastic Syndromes | Leukemia | Opportunistic Infections | GvHD | Graft-versus-Host Disease

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
GlaxoSmithKline

Terminated

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Neoplasms

United States, Canada
Novartis Pharmaceuticals

Completed

A Rollover Study to Provide Continued Treatment With Eltrombopag

Thrombocytopaenia

Belgium, Greece, Netherlands, Romania, China, Korea, Republic of, Tunisia, France, Hong Kong, Ireland, Peru, Poland
Takeda

Completed

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Neoplasms | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Renal Insufficiency | Leukemia, Myelomonocytic, Chronic | Liver Disease

United States, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm

United States
Rhizen Pharmaceuticals SA

Withdrawn

Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Brian Jonas
Pharmacyclics LLC.

Completed

Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Refractory Anemia With Excess Blasts in Transformation

United States
Millennium Pharmaceuticals, Inc.

Completed

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic

United States, Israel, Spain, France, Ireland, Canada, Germany, Czechia, Italy, Netherlands, Belgium, Bulgaria
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
Bellicum Pharmaceuticals

Active, not recruiting

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Hematologic Malignancy

Italy
Bellicum Pharmaceuticals

Active, not recruiting

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

Lymphoma, Non-Hodgkin | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Anemia, Aplastic | Primary Immune Deficiency Disorder | Cytopenia | Osteopetrosis | Leukemia, Acute Myeloid (AML), Child | Hemoglobinopathy in Children

United States
Brenda Cooper, MD
National Cancer Institute (NCI)

Completed

Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
Janssen Research & Development, LLC
argenx

Withdrawn

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United Kingdom, Switzerland, Italy, Germany, France, Spain, Australia, Turkey, Brazil, Russian Federation, Saudi Arabia
Incyte Corporation

Terminated

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Solid Tumors

United States, Belgium, France
Memorial Sloan Kettering Cancer Center
Pediatric Brain Tumor Consortium

Terminated

A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia

Fanconi Anemia | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML)

United States
Peter Bader

Active, not recruiting

CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.

Myelodysplastic Syndromes | Acute Leukemia

Germany
H. Lee Moffitt Cancer Center and Research Institute
Aprea Therapeutics

Completed

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm

United States
Incyte Corporation

Terminated

Study of INCB053914 in Subjects With Advanced Malignancies

Solid Tumors

United States
Technische Universität Dresden

Completed

Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza) (RELAZA2)

Myelodysplastic Syndrome | Acute Myelocytic Leukemia

Germany
Daiichi Sankyo, Inc.

Terminated

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Weill Medical College of Cornell University

Completed

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

Myelodysplastic Syndromes | Leukemia, Erythroblastic, Acute

United States
Case Comprehensive Cancer Center

Completed

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Neoplasm

United States
Grupo Cooperativo de Hemopatías Malignas

Withdrawn

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Mexico
Onconova Therapeutics, Inc.

Completed

Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States, France
Christopher Dvorak

No longer available

Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

Acute Myeloid Leukemia | Leukocyte Disorders | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Cytopenias | Immune Deficiency | Lymphomas | Bone Marrow Failure | Osteopetrosis | Hemoglobinopathy | Anemia Due to Intrinsic Red Cell Abnormality

United States
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

AML | MDS | CMML

United States, Canada
M.D. Anderson Cancer Center

Completed

Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Leukemia

United States
Novartis Pharmaceuticals

Completed

A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)

Japan
Daniel El Fassi
Technical University of Denmark

Completed

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML (AZACTA)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Denmark

Search clinical trials for: pediatric leukemia myelodysplastic syndrome azacitidine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations